WO2013130584A2 - Formulation containing ws727713 - Google Patents

Formulation containing ws727713 Download PDF

Info

Publication number
WO2013130584A2
WO2013130584A2 PCT/US2013/027991 US2013027991W WO2013130584A2 WO 2013130584 A2 WO2013130584 A2 WO 2013130584A2 US 2013027991 W US2013027991 W US 2013027991W WO 2013130584 A2 WO2013130584 A2 WO 2013130584A2
Authority
WO
WIPO (PCT)
Prior art keywords
solid formulation
compound
salt
hydrophilic substance
disintegrant
Prior art date
Application number
PCT/US2013/027991
Other languages
English (en)
French (fr)
Other versions
WO2013130584A3 (en
Inventor
Shigeo Takemura
Daisuke Tsunashima
Masakasu MIYAZAKI
Original Assignee
Telsar Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telsar Pharma Inc. filed Critical Telsar Pharma Inc.
Publication of WO2013130584A2 publication Critical patent/WO2013130584A2/en
Publication of WO2013130584A3 publication Critical patent/WO2013130584A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2013/027991 2012-02-29 2013-02-27 Formulation containing ws727713 WO2013130584A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-044462 2012-02-29
JP2012044462A JP2013180961A (ja) 2012-02-29 2012-02-29 Ｗｓ７２７７１３含有固形製剤

Publications (2)

Publication Number Publication Date
WO2013130584A2 true WO2013130584A2 (en) 2013-09-06
WO2013130584A3 WO2013130584A3 (en) 2015-07-02

Family

ID=49083442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/027991 WO2013130584A2 (en) 2012-02-29 2013-02-27 Formulation containing ws727713

Country Status (2)

Country Link
JP (1) JP2013180961A (ja)
WO (1) WO2013130584A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775832B2 (en) 2014-06-24 2017-10-03 Astellas Pharma Inc. Pharmaceutical composition for oral administration
CN110840855A (zh) * 2019-11-27 2020-02-28 哈尔滨珍宝制药有限公司 依托考昔片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
DE602005026380D1 (de) * 2004-04-08 2011-03-31 Astellas Pharma Inc Verbindung ws727713
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
CA2737528A1 (en) * 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775832B2 (en) 2014-06-24 2017-10-03 Astellas Pharma Inc. Pharmaceutical composition for oral administration
CN110840855A (zh) * 2019-11-27 2020-02-28 哈尔滨珍宝制药有限公司 依托考昔片及其制备方法

Also Published As

Publication number Publication date
JP2013180961A (ja) 2013-09-12
WO2013130584A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP5750847B2 (ja) アトルバスタチン経口投与用粒子状医薬組成物
US11433031B2 (en) Method for manufacturing acetaminophen preparation
JP2009542647A (ja) メマンチン医薬組成物
TWI804919B (zh) 含藥物之立即釋放錠劑及形成該錠劑的方法
CN101103965A (zh) 含有无定形头孢托仑酯的稳定固体制剂及其制备方法
MX2015000971A (es) Formulaciones y metodos para elaborar formulaciones para utilizarse en evacuacion colonica.
JP2017014289A (ja) トピラマート含有固形製剤
KR101762947B1 (ko) 내복 고형제제 및 그 제조 방법
JP6775155B2 (ja) 錠剤
WO2013130584A2 (en) Formulation containing ws727713
CN108420798A (zh) 一种抗凝剂的速释药物制剂及其制备方法
WO2023213878A1 (en) Solid tablet dosage form of ridinilazole
JP4173577B2 (ja) 固形安中散製剤
JP2016084469A (ja) 打錠用アルキルセルロース及びこれを含む固形製剤
US11458102B2 (en) Acetaminophen preparation, and method for producing same
CN112972396A (zh) 一种非布司他控释组合物及其制备方法
JPWO2019131753A1 (ja) 環状口腔内崩壊錠
EP3072528B1 (en) Composition comprising vemurafenib and cationic copolymer based on methacrylates
EP3072529B1 (en) Composition comprising vemurafenib and hpmc-as
JP7109255B2 (ja) 粉砕物の製造方法及び錠剤の製造方法
WO2022042646A1 (zh) 盐酸鲁拉西酮组合物及其制备方法
CN114748438A (zh) 一种阿伐普利尼片组合物及其制备方法
JP2021167306A (ja) 崩壊性粒子の製造方法
JP2017165724A (ja) アルキルセルロースを含む固形製剤及びその製造方法
JP2010265240A (ja) 固形製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13754314

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13754314

Country of ref document: EP

Kind code of ref document: A2